A phase I/II dose escalation study of 153-Samarium EDTMP (153-Sm-EDMTP) with fixed dose melphalan peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM).

被引：0
|
作者：
Dispenzieri, A
Wiseman, G
Lacy, MQ
Litzow, MR
Tefferi, A
Inwards, DJ
Micallef, IN
Gastineau, DA
Ansell, S
Rajkumar, SV
Fonseca, R
Porrata, L
Witzig, TE
Lust, JA
Kyle, RA
Greipp, PR
Gertz, MA
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Nucl Radiol, Rochester, MN USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2855
引用
收藏
页码：682A / 683A
页数：2
相关论文
共 50 条
  • [1] A phase II study of high dose 153-samarium EDTMP (153-sm EDMTP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM)
    Dispenzieri, A
    Wiseman, GA
    Lacy, MQ
    Geyer, S
    Litzow, MR
    Tefferi, A
    Inwards, DJ
    Micallef, IN
    Ansell, S
    Gastineau, DA
    Porrata, L
    Elliott, MA
    Gertz, MA
    BLOOD, 2003, 102 (11) : 982A - 982A
  • [2] A phase I study of a conditioning regimen for peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM):: 153Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDMTP) and melphalan.
    Dispenzieri, A
    Wiseman, GA
    Lacy, MQ
    Litzow, MR
    Tefferi, A
    Inwards, DJ
    Gastineau, DA
    Ansell, S
    Micalef, I
    Rajkumar, SV
    Fonseca, R
    Witzig, TE
    Lust, JA
    Kyle, RA
    Greipp, PR
    Gertz, MA
    BLOOD, 2000, 96 (11) : 558A - +
  • [3] Phase I high dose 153samarium ethylenediaminetetramethylenephosphonate (153-Sm EDTMP) and melphalan therapy of multiple myeloma (MM) with peripheral blood stem cell (PBSC) support.
    Wiseman, GA
    Dispenzieri, A
    Anderson, PM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 155P - 155P
  • [4] A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    G A Wiseman
    M Q Lacy
    M R Litzow
    P M Anderson
    D A Gastineau
    A Tefferi
    D J Inwards
    I N M Micallef
    S M Ansell
    L Porrata
    M A Elliott
    J A Lust
    P R Greipp
    S V Rajkumar
    R Fonseca
    T E Witzig
    C Erlichman
    J A Sloan
    M A Gertz
    Leukemia, 2005, 19 : 118 - 125
  • [5] A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Dispenzieri, A
    Wiseman, GA
    Lacy, MQ
    Litzow, MR
    Anderson, PM
    Gastineau, DA
    Tefferi, A
    Inwards, DJ
    Micallef, INM
    Ansell, SM
    Porrata, L
    Elliott, MA
    Lust, JA
    Greipp, PR
    Rajkumar, SV
    Fonseca, R
    Witzig, TE
    Erlichman, C
    Sloan, JA
    Gertz, MA
    LEUKEMIA, 2005, 19 (01) : 118 - 125
  • [6] A phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Dispenzieri, Angela
    Wiseman, Gregory A.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Kumar, Shaji K.
    Buadi, Francis
    Dingli, David
    Laumann, Krista M.
    Allred, Jake
    Geyer, Susan M.
    Litzow, Mark R.
    Gastineau, Dennis A.
    Inwards, David J.
    Micallef, Ivana N.
    Ansell, Stephen M.
    Porrata, Luis
    Elliott, Michelle A.
    Johnston, Patrick B.
    Hogan, William J.
    Gertz, Morie A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (06) : 409 - 413
  • [7] Phase I dose escalation of intravenous busulfan (Bu) with a fixed dose of melphalan (Mel) in patients (pts) with multiple myeloma (MM) undergoing autologous peripheral blood stem cell transplant (PBSCT).
    Callander, NS
    Cortes, R
    Freytes, CO
    Gokmen, E
    Ochoa, L
    Tran, HT
    Nguyen, J
    Roodman, GD
    BLOOD, 2001, 98 (11) : 201A - 201A
  • [8] High dose samarium-153 EDTMP (ethylenediaminetetramethylene phosphonic acid) and Melphalan chemotherapy with peripheral blood stem cell rescue for therapy of patients with multiple myeloma: Phase I and II clinical trial preliminary results.
    Wiseman, GA
    Dispensieri, A
    Lacy, MQ
    Gertz, MA
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 174P - 175P
  • [9] Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.
    Durrant, S
    Irving, I
    Mollee, P
    Morton, AJ
    Webb, M
    Macfarlane, D
    BONE MARROW TRANSPLANTATION, 2001, 27 : S41 - S41
  • [10] A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM).
    Hong, Sung H.
    Siegel, David S.
    Donato, Michele L.
    Vesole, David H.
    Pecora, Andrew L.
    Richter, Joshua R.
    Brown, Emily
    Buttner, Kathryn
    DelFavero, Marie
    Kim, Daniel
    Ortega, Andrea
    Rowley, Scott D.
    BLOOD, 2012, 120 (21)
12345